Ovarian reserve in breast cancer: Assessment with anti-Müllerian hormone

Reproductive BioMedicine Online

Volumn 29, Issue 5, 2014, Pages 573-580

  Hamy, Anne Sophie ^a   Porcher, Raphaël ^b,c   Cuvier, Caroline ^a   Giacchetti, Sylvie ^a   Schlageter, Marie Hélène ^a   Coussieu, Christiane ^b,c   Gronier, Héloise ^a   Feugeas, Jean Paul ^a   Adoui, Nadir ^a   Lacorte, Jean Marc ^b,c   Poirot, Catherine ^d   Habdous, Mohamed ^a   Espié, Marc ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AMH; breast cancer; chemotherapy; ovarian reserve

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LAROTAXEL; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGE; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONVALESCENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FERTILITY PRESERVATION; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LIMIT OF DETECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVARIAN RESERVE; RETROSPECTIVE STUDY; TIME TO TREATMENT; ADOLESCENT; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; MENSTRUATION; OVARIECTOMY; OVARY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AMENORRHEA; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MENSTRUATION; OVARIAN RESERVE; OVARIECTOMY; OVARY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908461792     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2014.07.008     Document Type: Article

References (34)

1. Anders C., Marcom P.K., Peterson B., Gu L., Unruhe S., Welch R., Lyons P., Behera M., Copland S., Kimmick G., Shaw H., Snyder S., Antenos M., Woodruff T., and Blackwell K. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer Cancer Invest 26 2008 286 295
2. Anderson R.A., and Cameron D.A. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer J. Clin. Endocrinol. Metab 96 2011 1336 1343
3. Anderson R.A., Themmen A.P.N., Qahtani A.A., Groome N.P., and Cameron D.A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer Hum. Reprod 21 2006 2583
4. Brougham M.F.H., Crofton P.M., Johnson E.J., Evans N., Anderson R.A., and Wallace W.H.B. Anti-mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study J. Clin. Endocrinol. Metab 97 2012 2059 2067
5. Decanter C., Morschhauser F., Pigny P., Lefebvre C., Gallo C., and Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results Reprod. Biomed. Online 20 2010 280 285
6. Dieudonné A.-S., Vandenberghe J., Geerts I., Billen J., Paridaens R., Wildiers H., and Neven P. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor Menopause 18 2011 821 824
7. Hansen K.R., Hodnett G.M., Knowlton N., and Craig L.B. Correlation of ovarian reserve tests with histologically determined primordial follicle number Fertil. Steril 95 2011 170 175
8. Hehenkamp W.J.K., Looman C.W.N., Themmen A.P.N., de Jong F.H., Te Velde E.R., and Broekmans F.J.M. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation J. Clin. Endocrinol. Metab 91 2006 4057 4063
9. Henry N.L., Xia R., Schott A.F., McConnell D., Banerjee M., and Hayes D.F. Prediction of postchemotherapy ovarian function using markers of ovarian reserve Oncologist 19 2013 68 74
10. Kelsey T.W., Wright P., Nelson S.M., Anderson R.A., and Wallace W.H.B. A validated model of serum anti-müllerian hormone from conception to menopause PLoS ONE 6 2011 e22024
11. Kumar A., Kalra B., Patel A., McDavid L., and Roudebush W.E. Development of a second generation anti-Müllerian hormone (AMH) ELISA J. Immunol. Methods 362 2010 51 59
12. La Marca A., Stabile G., Artenisio A.C., and Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle Hum. Reprod 21 2006 3103 3107
13. La Marca A., Sighinolfi G., Radi D., Argento C., Baraldi E., Artenisio A.C., Stabile G., and Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) Hum. Reprod. Update 16 2010 113 130
14. Loh J.S., and Maheshwari A. Anti-Mullerian hormone-is it a crystal ball for predicting ovarian ageing? Hum. Reprod 26 2011 2925 2932
15. Lutchman Singh K., Muttukrishna S., Stein R.C., McGarrigle H.H., Patel A., Parikh B., Groome N.P., Davies M.C., and Chatterjee R. Predictors of ovarian reserve in young women with breast cancer Br. J. Cancer 96 2007 1808 1816
16. Morgan S., Anderson R.A., Gourley C., Wallace W.H., and Spears N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Update 18 2012 525 535
17. Münsterberg A., and Lovell-Badge R. Expression of the mouse anti-müllerian hormone gene suggests a role in both male and female sexual differentiation Development 113 1991 613 624
18. Nardo L.G., Gelbaya T.A., Wilkinson H., Roberts S.A., Yates A., Pemberton P., and Laing I. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization Fertil. Steril 92 2009 1586 1593
19. Nelson S.M., Anderson R.A., Broekmans F.J., Raine-Fenning N., Fleming R., and La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum. Reprod 27 2012 631 636
20. Partridge A., Gelber S., Gelber R.D., Castiglione-Gertsch M., Goldhirsch A., and Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI Eur. J. Cancer 43 2007 1646 1653
21. Partridge A.H., Ruddy K.J., Gelber S., Schapira L., Abusief M., Meyer M., and Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer Fertil. Steril 94 2010 638 644
22. Powell K. Egg-making stem cells found in adult ovaries Nature 483 2012 16 17
23. R Development Core Team R: A Language and Environment for Statistical Computing n.d. 2009 R Foundation for Sta- tistical Computing Vienna, Austria
24. Reh A., Oktem O., and Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Fertil. Steril 90 2008 1635 1639
25. Rosendahl M., Andersen C.Y., Ernst E., Westergaard L.G., Rasmussen P.E., Loft A., and Andersen A.N. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study Hum. Reprod 23 2008 2475 2483
26. Rosendahl M., Andersen C.Y., la Cour Freiesleben N., Juul A., Løssl K., and Andersen A.N. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age Fertil. Steril 94 2010 156 166
27. Su H.I., Sammel M.D., Green J., Velders L., Stankiewicz C., Matro J., Freeman E.W., Gracia C.R., and DeMichele A. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors Cancer 116 2010 592 599
28. Sukumvanich P., Case L.D., Van Zee K., Singletary S.E., Paskett E.D., Petrek J.A., Naftalis E., and Naughton M.J. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study Cancer 116 2010 3102 3111
29. Thomas, A., O'Hara, B., Ligges, U., Sturtz, S., 2006. Making BUGS Open. R News 12-17.
30. Twisk J., and Rijmen F. Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects J. Clin. Epidemiol 62 2009 953 958
31. Van Disseldorp J., Lambalk C.B., Kwee J., Looman C.W.N., Eijkemans M.J.C., Fauser B.C., and Broekmans F.J. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts Hum. Reprod 25 2010 221 227
32. Van Rooij I.A.J., Broekmans F.J.M., te Velde E.R., Fauser B.C.J.M., Bancsi L.F.J.M.M., de Jong F.H., and Themmen A.P.N. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve Hum. Reprod 17 2002 3065 3071
33. Weenen C., Laven J.S.E., Von Bergh A.R.M., Cranfield M., Groome N.P., Visser J.A., Kramer P., Fauser B.C.J.M., and Themmen A.P.N. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment Mol. Hum. Reprod 10 2004 77 83
34. Yu B., Douglas N., Ferin M.J., Nakhuda G.S., Crew K., Lobo R.A., and Hershman D.L. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy Cancer 116 2010 2099 2105